• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Stryker Stock What Changed After Lowered Guidance

    Simply Wall St·11/02/2026 01:31:01
    Listen to the news
    • Stryker reported Q3 2026 sales of US$6,520 million and net income of US$753 million, alongside a US$293 million goodwill impairment and lower full year EPS guidance after operational and demand pressures in key lines.
    • The contrast between higher sales and weaker quarterly earnings, compounded by impairment charges and issues in manufacturing and SAP execution, highlights how cost structure, system rollouts and softer hip and knee procedure volumes are shaping Stryker's current earnings quality.
    • We will now examine how Stryker's lowered full year EPS guidance reshapes the investment narrative and its longer term earnings profile.

    Compare Stryker's pressure points with other medical technology stocks under earnings stress by scanning our hand picked list of list of solid balance sheet and fundamentals (24 results)

    Stryker Investment Narrative Recap

    Stryker appeals to shareholders who believe in long term demand for orthopaedics, robotics and hospital equipment, supported by a large installed base and a broad portfolio. The Q3 update challenges that belief in the near term, as execution issues in the SAP rollout, softer hips and knees, and peripheral vascular disruption all squeeze earnings.

    In the short term, the key swing factor is whether Stryker can stabilise procedure volumes and resolve operational bottlenecks without further profit compression. The biggest risk lies in extended manufacturing and regulatory pressures in peripheral vascular, as well as any lingering impact from legal investigations that could absorb management attention and increase costs.

    The most relevant piece of news for that thesis is the Q3 2026 report itself, including the US$293 million goodwill impairment and lower full year EPS guidance. Those figures, alongside revenue of US$6,520 million and net income of US$753 million for the quarter, provide a fresh view of how the business is handling stress.

    When you compare that with the longer term catalysts such as Mako robotics expansion, hospital capital spending and eventual peripheral vascular recovery, the question becomes one of execution timing. The story now focuses less on finding new growth ideas and more on converting the existing program into cleaner margins and steadier earnings.

    What Stryker's Long Range Forecasts Assume

    Stryker's narrative projects US$32.9 billion revenue and US$7.7 billion earnings by 2029. That path assumes 7.7% yearly revenue growth and an earnings increase of US$4.1 billion from US$3.6 billion today.

    Uncover why Stryker's fair value indicates a 20% potential upside to its current price, which could narrow quickly.

    NYSE:SYK 1-Year Stock Price Chart
    NYSE:SYK 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view puts Stryker’s hip and knee exposure at the center of the story. The most cautious analysts were already penciling in 6.5% annual revenue growth and about US$6.5b of earnings by 2029 before this Q3 impairment and guidance cut. That is a much tougher script. Use it as a prompt to compare multiple forecasts yourself.

    Explore 6 other Stryker fair value estimates, including one that suggests it could be worth just $311.21.

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking for more Stryker-sized investment ideas?

    If this update on Stryker sharpened your questions about quality, risk and income potential, use that same framework across the wider market with the Simply Wall St Screener before you commit fresh capital.